Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models

Stock Information for Xenetic Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Xenetic Biosciences Inc.

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma
Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.